SG Americas Securities LLC lessened its stake in Celgene Co. (NASDAQ:CELG) by 58.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 60,558 shares of the biopharmaceutical company’s stock after selling 84,002 shares during the quarter. SG Americas Securities LLC’s holdings in Celgene were worth $6,013,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of CELG. First Trust Advisors LP boosted its position in shares of Celgene by 1.7% during the 3rd quarter. First Trust Advisors LP now owns 523,581 shares of the biopharmaceutical company’s stock valued at $51,992,000 after acquiring an additional 8,650 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in shares of Celgene by 0.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 48,322 shares of the biopharmaceutical company’s stock valued at $4,799,000 after acquiring an additional 145 shares during the last quarter. Manchester Capital Management LLC boosted its position in shares of Celgene by 6.5% during the 3rd quarter. Manchester Capital Management LLC now owns 10,404 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 636 shares during the last quarter. Donaldson Capital Management LLC acquired a new position in shares of Celgene during the 3rd quarter valued at about $355,000. Finally, Bartlett & Co. LLC boosted its position in shares of Celgene by 143.2% during the 3rd quarter. Bartlett & Co. LLC now owns 535 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 315 shares during the last quarter. 72.31% of the stock is owned by institutional investors.
Several research analysts have recently weighed in on the stock. Robert W. Baird cut shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price target on the stock. in a research report on Friday, November 1st. Cowen restated a “hold” rating and issued a $102.00 price objective on shares of Celgene in a report on Tuesday, July 30th. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective on the stock in a report on Tuesday, July 23rd. Leerink Swann set a $115.00 price objective on shares of Celgene and gave the company a “hold” rating in a report on Friday, November 1st. Finally, Wells Fargo & Co set a $110.00 price objective on shares of Celgene and gave the company a “hold” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $97.31.
In other news, insider Terrie Curran sold 11,338 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares of the company’s stock, valued at $1,325,957.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.39% of the stock is currently owned by corporate insiders.
NASDAQ:CELG traded up $0.54 on Friday, reaching $109.54. 5,706,800 shares of the company’s stock were exchanged, compared to its average volume of 6,764,924. The business has a fifty day moving average of $102.54 and a 200-day moving average of $96.76. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. The firm has a market capitalization of $76.64 billion, a price-to-earnings ratio of 14.39, a price-to-earnings-growth ratio of 0.51 and a beta of 1.41. Celgene Co. has a 52-week low of $58.59 and a 52-week high of $109.75.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.70 by $0.29. The business had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The company’s revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 earnings per share. As a group, equities analysts anticipate that Celgene Co. will post 10.7 earnings per share for the current year.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Outstanding Shares
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.